Maglangit, Alma May G.
HRN: 21-89-56 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
09/15/2022
METRONIDAZOLE 5MG/ML, 100ML (VIAL)
09/15/2022
09/22/2022
IV
500mg
Q8h
AGE With Moderate DHN
Waiting Final Action
Indication: Empiric Type of Infection: Intra-abdominal Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes